# US 2019/0313934 A1 · Device and system for monitoring and treating muscle tension-related medical conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0313934 A1
- Document ID: US20190313934A1
- Status: Published application
- Kind: A1
- Application number: 16/308,777
- Filed: 2017-06-12
- Published: 2019-10-17
- Earliest claimed: 2016-06-10
- Assignees: Biotrak Health, Inc.
- Applicants: Biotrak Health, Inc.
- Inventors: Eric Lee; Robert L. Bratzler; Erk Lillydahl; Adam Kirell
- Web page: https://patentgrep.com/patent/US20190313934A1

## CPC

- A61B 5/389: Electromyography [EMG]
- A61B 5/0002: {Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network (endoradiosondes A61B5/07)}
- A61B 5/0022: {Monitoring a patient using a global network, e.g. telephone networks, internet}
- A61B 5/01: Measuring temperature of body parts {; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue} (clinical contact thermometers G01K13/20)
- A61B 5/02055: {Simultaneously evaluating both cardiovascular condition and temperature}
- A61B 5/14551: {for measuring blood gases}
- A61B 5/33: specially adapted for cooperation with other devices
- A61B 5/4824: {Touch or pain perception evaluation (A61B5/4821 takes precedence)}
- A61B 5/4839: {combined with drug delivery}
- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61B 5/486: {Biofeedback (using electroencephalography [EEG] A61B5/375)}
- A61B 5/6803: {Head-worn items, e.g. helmets, masks, headphones or goggles}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- A61B 5/746: {Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms}
- A61B 5/7465: {Arrangements for interactive communication between patient and care services, e.g. by using a telephone network (telemetry of measured physiological signal A61B5/0002)}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/612: having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid (fosfosal A61K31/661)
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 80/00: ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
- A61B 5/02405: {Determining heart rate variability}
- A61B 5/0533: Measuring galvanic skin response
- A61B 5/7405: {using sound}
- A61B 5/742: {using visual displays (displays for heart-related electrical signals, e.g. ECG, A61B5/339)}
- A61B 5/7455: {characterised by tactile indication, e.g. vibration or electrical stimulation}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Mobile systems and devices can employ surface electromyography (sEMG) technology and other sensing technologies for measuring muscle tension and managing chronic pain conditions. These systems and devices can sense and quantify excessive muscle tension and can facilitate management of excessive muscle tension and chronic pain through cognitive behavioral therapy, pharmacologic intervention, or a combination of both.

## Claims

### Claim 1

A system for detecting muscle tension, comprising:
a wearable device having at least one sensor unit configured to generate at least one output indicative of a level of muscle tension, and circuitry for processing the output.

### Claim 2 (depends on 1)

The system of claim 1, wherein processing the output comprises detecting when the output exceeds a threshold thereby indicating that a user of the wearable device is experiencing undesirable muscle tension.

### Claim 3 (depends on 2)

The system of claim 2, wherein the undesired muscle tension is excessive muscle tension or inadequate muscle tension.

### Claim 4 (depends on 2)

The system of claim 2, wherein processing the output further comprises providing an alert when the output exceeds the threshold.

### Claim 5 (depends on 4)

The system of claim 4, wherein the alert is one or more of a haptic alert, a visual alert, or an audible alert.

### Claim 6 (depends on 1)

The system of claim 1, wherein processing the output comprises transmitting the output to an app executing on a computing device.

### Claim 7 (depends on 6)

The system of claim 6, further comprising:
the app that is configured to receive the output transmitted by the circuitry of the wearable device and process the output to produce a real-time display indicative of the level of muscle tension.

### Claim 8 (depends on 7)

The system of claim 7, wherein the mobile or app is further configured to detect when the level of muscle tension exceeds a threshold and in response notify a user of the wearable device.

### Claim 9 (depends on 8)

The system of claim 8, wherein notifying the user includes presenting one or more treatment techniques that the user can perform to reduce the muscle tension.

### Claim 10 (depends on 9)

The system of claim 9, wherein the one or more treatment techniques include one or more relaxation techniques, one or more cognitive behavioral therapy techniques, and/or one or more pharmacologic agents.

### Claim 11 (depends on 9)

The system of claim 9, wherein the app is further configured to monitor the output after presenting the one or more treatment techniques to verify whether the one or more treatment techniques have reduced the muscle tension.

### Claim 12 (depends on 7)

The system of claim 7, wherein the mobile or app is configured to store the output over time and to analyze the stored output to detect patterns or trends in muscle tension.

### Claim 13 (depends on 7)

The system of claim 7, wherein the mobile or app is configured to transmit the output to one or more remote computing devices, servers, or cloud based storage system.

### Claim 14 (depends on 13)

The system of claim 13, wherein the one or more remote computing devices, servers, or cloud based storage system include a computing device, servers, or cloud based storage system of a healthcare provider with which the user has a relationship.

### Claim 15 (depends on 14)

The system of claim 14, wherein the mobile or computing device is configured to receive communications from a user of the one or more remote computing devices, servers, or cloud based storage system and to display the communications to the user of the wearable device, the communications including instructions for addressing the muscle tension.

### Claim 16 (depends on 13)

The system of claim 13, wherein the one or more remote computing devices, servers, or cloud based storage system include a computing device that receives output generated by a plurality of wearable devices worn by other users.

### Claim 17 (depends on 7)

The system of claim 7, wherein the mobile or app is further configured with telecommunication features to connect with a remote clinician.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A method for treating an indication, comprising use of the system of any of claims 1 through 17.

### Claim 19 (depends on 18)

The method of claim 18, further comprising administration of one or more pharmacologic agents, and/or one or more cognitive behavioral therapies intended to treat the indication.

### Claim 20 (depends on 18, 19)

The method of either claim 18 or 19, wherein the indication is selected from the group consisting of pain, inflammation, anxiety, depression, sleep-related disorders, hypertension, seizure, hyperlipidemia, ADHD, ADA, IBD, IBS, constipation, pelvic floor pain, incontinence, PTSD, and tinnitus.

### Claim 21 (depends on 18, 19, 20)

The method of any of claims 18 through 20, further comprising administering the one or more pharmacologic agents in response to an alert from the wearable device.

### Claim 22 (depends on 21)

The method of claim 21, wherein the step of administering further comprises modifying a regimen of the one or more pharmacologic agents to initiate, reduce, or terminate use of the pharmacologic agents.

### Claim 23 (depends on 18, 19, 20, 21)

The method of any of claims 18 through 21, further comprising administering at least one of a physical activity, physical therapy, a relaxation technique, a dietary restriction, counseling, a companion animal, cognitive behavioral therapy, cognitive processing therapy, and prolonged exposure therapy.

### Claim 24

A system for detecting an indication, comprising:
a wearable device having a sensor unit configured to detect one or more biological signals of the indication, the sensor unit further configured to generate an output indicative of the indication, and circuitry for processing the output.

### Claim 25 (depends on 24)

The system of claim 24, wherein processing the output comprises detecting when the output exceeds a threshold thereby indicating that a user of the wearable device is experiencing the one or more biological signals indicating undesirable muscle tension.

### Claim 26 (depends on 25)

The system of claim 25, wherein the one or more biological signals is selected from the group consisting of muscle tension, heart rate, temperature, EEG, EKG/ECG, GSR, HRV, and pulse oximetry.

### Claim 27 (depends on 24)

The system of claim 24, wherein the indication is selected from the group consisting of tension headache, migraine, TMJ/MPD, muscle pain, chronic pelvic pain, non-disc low back pain, hypercholesterolemia, PTSD, apnea, insomnia, bruxism, hypertension, ADD, ADHD, urinary incontinence, alcoholism, substance abuse, arthritis, chronic pain, fecal elimination disorders, traumatic brain injury, vulvar vestibulitis, epilepsy, dementia, Alzheimer's disease, multiple sclerosis, tinnitus, Crohn's disease, inflammatory bowel disease, constipation, anxiety, depression, vertigo, hyperlipidemia, and pain associated with cancer and post-concussion syndrome.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A method of treating an indication of claim 27 in a patient in need thereof that comprises (i) administration of an effective amount of at least one pharmacologic agent, and (ii) prescribing use of the system of any of claims 1 through 27.

### Claim 29 (depends on 28)

The method of claim 28, wherein the indication is a migraine.

### Claim 30 (depends on 29)

The method of claim 29, wherein the pharmacologic agent is selected from the group consisting of an analgesic, an NSAID, acetaminophen, barbiturates, antidopaminergic drugs, muscle relaxants, vasoconstrictors, anticonvulsants, beta blockers, serotonin antagonists, antidepressants, antihistamines, topiramate, amitriptyline, propranolol, fremanezumab, eptinezumab, galcanezumab, and erenumab, and other monoclonal antibodies peptides, biomolecules, and small molecule drugs for treating migraines.

### Claim 31 (depends on 28)

The method of claim 28, wherein the indication is multiple sclerosis.

### Claim 32 (depends on 31)

The method of claim 31, wherein the pharmacologic agent is selected from the group consisting of natalizumab, ocrelizumab, alemtuzumab, daclizumab, teriflunomide, fingolimod, mitoxantrone, other biologicals such as interferon beta-1a, interferon beta-1b, peginterferon beta-1a, and other small-molecule drugs, for treating multiple sclerosis.

### Claim 33 (depends on 28)

The method of claim 28, wherein the indication is acute and chronic pain conditions.

### Claim 34 (depends on 33)

The method of claim 33, wherein the pharmacologic agent is selected from the group consisting of analgesics, NSAIDs, opioids, and other biologicals or small-molecule drugs for pain management and treatment.

### Claim 35 (depends on 28)

The method of claim 28, wherein the indication is sleep disorder, including insomnia, sleep apnea, circadian rhythm disorders, restless leg syndrome, and narcolepsy.

### Claim 36 (depends on 35)

The method of claim 35, wherein the pharmacologic agent is selected from the group consisting of dopamine agonists, benzodiazepines, non-benzodiazepine hypnotics, melatonin receptor simulators, opiates, anticonvulsants, anti-narcoleptics, orexin receptor antagonists, suvorexant, eszopiclone, zaleplon, zolpidem, triazolam, temazepam, ramelteon, doxepin, trazodone, tiagabine, diphenhydramine, melatonin, tryptophan, valerian, and other drugs for treating sleep disorders.

### Claim 37 (depends on 28)

The method of claim 28, wherein the indication is anxiety.

### Claim 38 (depends on 37)

The method of claim 37, wherein the pharmacologic agent is selected from the group consisting of anti-anxiety drugs, antidepressants, steroids, misoprostol, lidocaine, Cymbalta, Effexor XR, citalopram, Paxil CR, escitalopram, quetiapine, sertraline, Paxil, venlafaxine, paroxetine, pregabalin, duloxetine, Pexeva, Irenka, Celexa, Prozac, sertraline, citalopram, fluoxetine, amitriptyline, venlafaxine, paroxetine, Prozac Weekly, Luvox CR, Luvox, prazosin, fluvoxamine, and other drugs for treating anxiety.

### Claim 39 (depends on 28)

The method of claim 28, wherein the indication is a neurologic disorder, comprising at least one of epilepsy, dementia, and Alzheimer's disease.

### Claim 40 (depends on 39)

The method of claim 39, wherein the pharmacologic agent is selected from the group consisting of brivaracetam, carbamazepine, diazepam, lorazepam, clonazepam, eslicarbazepine, ethosuximide, felbamate, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, phenobarbitol, phenytoin, pregabalin, tiagabine, topiramate, valproate, zonisamide, and other biologicals and small-molecule drugs for treating neurologic disorders.

### Claim 40 (depends on 41)

The method of claim 41, wherein the pharmacologic agent is selected from the group consisting of Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone (glatiramer acetate), Extavia (interferon beta-1b), Glatopa (glatiramer acetate), Plegridy (peginterferon beta-1a), Rebif (interferon beta-1a), Zinbryta (daclizumab), Aubagio (teriflunomide), Gilenya (fingolimod), Tecfidera (dimethyl fumarate), Lemtrada (alemtuzumab), Novantrone (mitoxantrone), Ocrevus (ocrelizumab), Tysabri (natalizumab), Paxil, Zoloft, Prozac, and other biologicals or small-molecule drugs for treating depression.

### Claim 41 (depends on 28)

The method of claim 28, wherein the indication is depression.

### Claim 41 (depends on 28)

The method of claim 28, wherein said indication is selected from the group consisting of tension headache, migraine, TMJ/MPD, muscle pain, chronic pelvic pain, non-disc low back pain, hypercholesterolemia, PTSD, apnea, insomnia, bruxism, hypertension, ADD, ADHD, urinary incontinence, alcoholism, substance abuse, arthritis, chronic pain, fecal elimination disorders, traumatic brain injury, vulvar vestibulitis, epilepsy, dementia, Alzheimer's disease, multiple sclerosis, tinnitus, Crohn's disease, IBD, constipation, anxiety, depression, vertigo, hyperlipidemia, and pain associated with cancer and post-concussion syndrome.

### Claim 42 (depends on 28)

The method of claim 28, wherein the indication manifests at least one biological signal detectable by the system.

### Claim 43 (depends on 42)

The method of claim 42, wherein the at least one biological signal is selected from the group consisting of muscle tension, heart rate, temperature, EEG, EKG/ECG, GSR, HRV, and pulse oximetry.

### Claim 44 (depends on 28)

The method of claim 28, further comprising alerting the patient via an output of the system.

### Claim 45 (depends on 44)

The method of claim 44, wherein the output comprises at least one of an audible signal, a visual signal, and a haptic signal.

### Claim 46 (depends on 45)

The method of claim 45, further comprising alerting the patient via an output of the system of at least one of (i) the presence of the at least one biological signal, (ii) the presence of the indication, (iii) a reminder, (iv) coaching, and (v) a remedial action for the indication.

### Claim 47 (depends on 46)

The method of claim 46, wherein at least one of the reminder, the coaching, and the remedial action for the indication alerts the patient to complete at least one of (i) administer the pharmacologic agent, (ii) complete a physical therapy exercise, (iii) complete a relaxation activity, and (iv) other forms of cognitive behavioral therapy.

### Claim 48 (depends on 47)

The method of claim 47, wherein the physical therapy exercise or relaxation exercise comprises at least one of stretching, deep breathing, controlled breathing, progressive muscle relaxation, focused muscle contractions, walking, meditation, eliminating light, changing position, and assuming a body position.

### Claim 49 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any of claims 28 through 48, further comprising administration of at least one of a physical activity, physical therapy, a relaxation technique, a dietary restriction, counseling, a companion animal, cognitive behavioral therapy, cognitive processing therapy, and prolonged exposure therapy.
